STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies

| · · · | Item No | Recommendation |
|--|---|---|
| Title and abstract | 1 🗸 (a) Indi | cate the study's design with a commonly used term in the title or the abstract |
| | V(b) Prov | vide in the abstract an informative and balanced summary of what was done |
| · · · | and what | at was found |
| Introduction | | |
| Background/rationale | 2 🗸 Explain | the scientific background and rationale for the investigation being reported |
| Objectives | 3 V State sp | ecific objectives, including any prespecified hypotheses |
| Methods | | |
| Study design | 4 V Present | key elements of study design early in the paper |
| Setting | 5 🗸 Describ | e the setting, locations, and relevant dates, including periods of recruitment, |
| | | re, follow-up, and data collection |
| Participants | 6 V (a) Give | e the eligibility criteria, and the sources and methods of selection of |
| | particip | ants |
| Variables | 7 V Clearly | define all outcomes, exposures, predictors, potential confounders, and effect |
| | modifie | rs. Give diagnostic criteria, if applicable |
| Data sources/ | 8* 🗸 For eac | h variable of interest, give sources of data and details of methods of |
| measurement | assessm | ent (measurement). Describe comparability of assessment methods if there i |
| | more th | an one group |
| Bias | 9 🗸 Describ | e any efforts to address potential sources of bias |
| Study size | 10 🗸 Explain | how the study size was arrived at NO need |
| Quantitative variables | 11 🧹 Explain | how quantitative variables were handled in the analyses. If applicable, |
| | describe | e which groupings were chosen and why NO Need |
| Statistical methods | $12 \sqrt{(a) \text{ Desc}}$ | cribe all statistical methods, including those used to control for confounding |
| | (b) Desc | cribe any methods used to examine subgroups and interactions |
| | (c) Expl | ain how missing data were addressed |
| | (<i>d</i>) If ap | plicable, describe analytical methods taking account of sampling strategy |
| | (<u>e</u>) Desc | cribe any sensitivity analyses |
| Results | a de la caractería de la c | |
| Participants | 13*1⁄ (a) Repo | ort numbers of individuals at each stage of study—eg numbers potentially |
| | eligible, | examined for eligibility, confirmed eligible, included in the study, |
| | complet | ing follow-up, and analysed |
| | (b) Give | e reasons for non-participation at each stage |
| | (c) Cons | sider use of a flow diagram |
| Descriptive data | 14*/ (a) Give | characteristics of study participants (eg demographic, clinical, social) and |
| | informa | tion on exposures and potential confounders |
| 이 동안 한 동안 한 10년 1월 14일 - 11월 14일 - 11월 14일 - 11월 14일 - 11월 14일 11월 14일 - 11월 1 | (b) India | cate number of participants with missing data for each variable of interest |
| Outcome data | 15∗∨ Report r | numbers of outcome events or summary measures |
| Main results | 16 🗸 (a) Give | e unadjusted estimates and, if applicable, confounder-adjusted estimates and |
| | their pre | ecision (eg, 95% confidence interval). Make clear which confounders were |
| | adjusted | for and why they were included |
| | (b) Repo | ort category boundaries when continuous variables were categorized |
| | (c) If rel | evant, consider translating estimates of relative risk into absolute risk for a |
| °aria∑ ariarra an | meaning | ful time period |
| Other analyses | 17 Report of | other analyses done—eg analyses of subgroups and interactions, and |
| | sensitivi | ty analyses No mead |

| Discussion | |
|-------------------|---|
| Key results | 18 V Summarise key results with reference to study objectives |
| Limitations | 19 V Discuss limitations of the study, taking into account sources of potential bias or |
| | imprecision. Discuss both direction and magnitude of any potential bias |
| Interpretation | $20 \bigvee$ Give a cautious overall interpretation of results considering objectives, limitations, |
| | multiplicity of analyses, results from similar studies, and other relevant evidence |
| Generalisability | 21 V Discuss the generalisability (external validity) of the study results |
| Other information | |
| Funding | 22 Give the source of funding and the role of the funders for the present study and, if |
| | applicable, for the original study on which the present article is based No free |

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.